Scott & Christie and Associates
Trial Types
- Allergy
- Blepharitis
- Dry Eye
- Glaucoma (Pharmaceutical)
- Glaucoma (Surgical)
- Intraocular Lens (IOL)
- Post Cataract Inflammation
- Presbyopia
- Viscoelastic
Site Accolades
Among top enrollers in studies with these noteworthy, FDA-approved meds:
- Tyrvaya
- Xiidra
- Vuity
- Miebo
- Xdemvy
- Omlonti
- Vyzulta
- Rocklatan
- Rhopressa
- Durysta
Our History
Scott & Christie Eyecare Associates is an extension of the ophthalmology practice of the late Dorothy Christie Scott, MD. Dr. Scott was a pioneer in the field, becoming one of only a few female ophthalmologists in the Pittsburgh area when she began her practice in 1958. William C. Christie, MD, acquired Dr. Scott’s practice on July 1, 1990, and incorporated shortly thereafter as Scott & Christie Eyecare Associates, PC. We currently offer services at offices located in Fox Chapel and Cranberry Township. In addition to those locations, Scott & Christie Eyecare Associates is affiliated with the Surgery Center at Cranberry. This relationship enables the company to offer a more diverse range of services to optometrists and their patients within one facility.
Our Focus: Vision For Life
The team at Scott & Christie Eyecare Associates believes in serving our patients with compassion and understanding while delivering the latest technological innovations in ocular diagnostics and treatment.
We believe in continually seeking higher standards of care to serve patients’ eyecare needs with comfortable offices, experienced doctors and staff, and convenient, comfortable locations for them. Our patients tell us that, “We treat them like family.” And that is important to us.
Our Culture
Scott & Christie Eyecare Associates, PC, is defined by teamwork. The service patients receive is the culmination of successful coordination by our surgeons, optometrists, employees, pharmaceutical companies, vendors and insurance companies. This seamless integration results in higher standards of care for our patients.
Investigators
Locations
The Surgery Center at Cranberry
105 Brandt Drive #201
Cranberry Township, PA 16066
- 724-772-5420
- 724-772-5423
Cranberry Shoppes (Good Looks Eyewear)
20215 U.S. 19
Cranberry Township, PA 16066
- 724-772-9090
- 724-772-9160
Awards and Publications
Publications
William C. Christie, MD, Scott & Christie Eyecare Associates
- Christie W, et al. Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients With Open-Angle Glaucoma or Ocular Hypertension. Clinical Ophthalmology 2023:I7 3023-3036.
- Weinreb R, Christie W, Medeiros F, Craven R, Kim K, Nguyen A, Bejanian M, Wirta D. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes. Ophthalmol Glaucoma, 2023.
- Chang D, Thompson V, Christie W, Chu Y, Vida R. Clinical Evaluation of a Modified Light Transmission Short-Wavelength Filtering Intraocular Lens Compared to a Colorless Control. Ophthalmol Ther, 2023.
- Chang D, Janakiraman D, Smith P, Buteyn A, Domingo J, Jones J, Christie W. Visual Outcomes and Safety of an Extended Depth-of-focus Intraocular Lens: Results of a Pivotal Clinical Trial. J Cataract Refract Surg, Mar 2022.
- Shirneshan E, Wirta D, Christie W, Tauber J, Lee S, Campbell J. Assessing Presbyopia Impacts and Coping Behaviors with a de Novo PRO Instrument in a Phase 4 Study of AGN-190584 (Pilocarpine 1.25%). Invest. Ophthalmol. Vis. Sci. 2021;62(8):2912.
- Christie W, Tauber J, Jerkins G, Fangqui Z, Tepelus T, Penzner J, Liu H, Safyan E, Robinson M. Gemini 1 Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia. ARVO Congress Presentation, 2021.
- Christie W, Jerkins G, Tauber J, Fangqui Z, Tepelus T, Safyan E. Gemini I Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia. ASCRS Symposium on Cataract, IOL, & Refractive Surgery Congress Presentation, 2021.
- Wirta D, Christie W, Tauber J, Shirneshan E, Lee S, Campbell J. Assessing Presbyopia Impacts and Coping Behaviors with a de Novo PRO Instrument in a Phase 3 Study of AGN-190584 (Pillocarpine 1.25%). ASCRS Symposium on Cataract, IOL, & Refractive Surgery Congress Presentation, 2021.
- Craven E, Walters T, Christie W, Day D, Lewis R, Goodkin M, Chen M, Wangsadipura V, Robinson M, Bejanian M. Bimatoprost SR Study Group. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients. Drugs, Feb 2020.
- Chang D, Christie W, Loden J, Smith P, Jackson B. Clinical evaluation of a bacterially derived sodium hyaluronate 2.3% ophthalmic viscosurgical device. J Cataract Refract Surg, Dec 2019.
- Lewis R, Christie W, Day D, Craven E, Walters T, Bejanian M, Lee S, Goodkin M, Zhang J, Whitcup S, Robinson M. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. Am J Ophthalmol, Mar 2017.
- Walters T, Lewis R, Christie W, Day D, Craven E, Bejanian M, Lee S, Goodkin M, Zhang J, Whitcup S, Robinson M. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. ASCRS ASOA Symposium Presentation, 2016.
- Jones J, Christie W, Buteyn A. Visual Outcomes of a New Extended Range of Vision IOL. ASCRS ASOA Symposium Presentation, 2016.
- Lewis R, Christie W, Day D, Craven R, Bejanian M, Lee S, Goodkin M, Zhang J, Robinson M. Bimatoprost Sustained-Release Implants for Glaucoma Terapy: Interim Results From a 24-Month Phase 1/2 Clinical Trial. AAO Poster Presentation, 2015.
- Modi S, Lehmann R, Walters T, Fong R, Christie W, Roel L, Nethery D, Sager D, Tsorbatzoglou A, Philipson B, Traverso C, Reiser H. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg, 2014 Feb;40(2):203-11.